Jean Rodrigo Tafarel¹, Isabela Busto Silva², Isadora Busto Silva³*, Luiz Augusto Fanhani Cracco², Vanessa Martins Torres² and Larissa Uhlmann Wendling⁴

¹Gastroenterologist and Hepatologist, Internal Medicine Department, Hospital Universitário Cajuru, Curitiba, Parana, Brazil
²Medical Resident Internal Medicine Department, Hospital Universitário Cajuru, Curitiba, Parana, Brazil
³Medical Student, Federal University of Paraná, Curitiba, Parana, Brazil
⁴Pathologist, Curitiba, Parana, Brazil

*Corresponding Author: Isadora Busto Silva, Medical Student, Federal University of Paraná, Martin Afonso, Curitiba, Parana, Brazil.

Received: August 03, 2021 Published: September 08, 2021

Citation: Isadora Busto Silva., et al. “Vanishing Bile Duct Syndrome due to Valproic Acid: A Rare Case". Acta Scientific Gastrointestinal Disorders 4.10 (2021): 13-16.

Abstract

  Vanishing bile duct syndrome (VBDS) is a rare acquired condition, described by the progressive loss of intrahepatic bile ducts, leading to ductopenia and cholestasis. It can be associated with adverse drug reactions, cancer, and autoimmune liver diseases. The diagnosis is confirmed when there are less than 50% of the bile ducts on histopathological analysis. The prognosis is variable and it is depends on the etiology of the bile duct injury. We report a case of a 47-year-old man with chronic cholestatic condition associated with the use of valproic acid, in which the investigation confirmed VBDS in the histopathological analysis.

Keywords: Adverse Drug Reaction; Bile Duct Disease; Cholestasis; Case Report; Vanishing Bile Duct Syndrome

Bibliography

1. Greca Raquel D., et al. “Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case”. Annals of Hepatology1 (2020): 107-112.
2. Bakhit Mena., et al. “Vanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review”. World Journal of Gastroenterology2 (2017): 366.
3. Sundaram Vinay and Björnsson Einar S. “Drug‐induced cholestasis”. Hepatology Communications8 (2017): 726-735.
4. Bak Haein., et al. “A Case of Vanishing Bile Duct Syndrome after Drug-Induced Liver Injury Caused by Pelubiprofen”. Yonsei Medical Journal12 (2020): 1060.
5. Bryant Alton E and Dreifuss Fritz E. “Valproic acid hepatic fatalities. III. US experience since 1986”. Neurology2 (1996): 465-469.
6. Ludwig J., et al. “Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis”. Journal of Hepatology 2 (1988): 193-199.
7. Miyakawa H., et al. “Detecção de autoanticorpos antimitocondriais em pacientes imunofluorescentes AMA-negativos com cirrose biliar primária usando auto-antígenos recombinants”. Hepatology 34 (2001): 243.
8. Sherlock Sheila. “The syndrome of disappearing intrahepatic bile ducts”. The Lancet8557 (1987): 493-496.
9. Zoubek ME., et al. “Systematic review: ibuprofen-induced liver injury”. Alimentary Pharmacology and Therapeutics 51 (2020): 603-611.
10. Hussaini S Hyder and Farrington Elizabeth A. “Idiosyncratic drug-induced liver injury: an overview”. Expert Opinion on Drug Safety6 (2007): 673-684.
11. Levine Calley., et al. “Severe ductopenia and cholestasis from levofloxacin drug-induced liver injury: a case report and review. In: Seminars in liver disease”. Thieme Medical Publishers (2014): 246-251.
12. Leise Michael D., et al. “Drug-induced liver injury”. In: Mayo clinic proceedings. Elsevier (2014): 95-106.
13. Síndrome do desaparecimento do ducto biliar”. LiverTox: Informações clínicas e de pesquisa sobre lesão hepática induzida por drogas. Bethesda (MD): Instituto Nacional de Diabetes e Doenças Digestivas e Renais (2012).

Copyright: © Isadora Busto Silva., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.